China NMPA Approves Rona’s IND for RN1871 siRNA Drug for Hypertension

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved by China’s National Medical Products Administration (NMPA).

RN1871 is designed to silence AGT mRNA expression in the liver, precisely inhibiting the production of the key precursor protein in the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS pathway plays a key role in blood pressure regulation, and its overactivation is closely linked to the progression of hypertension. Preclinical studies have demonstrated that RN1871 delivers long-lasting blood pressure control offering a promising new therapeutic option for over 1.5 billion hypertension patients worldwide.

Stella Shi, CEO and founder of Rona Therapeutics, stated: “The IND approval of RN1871 marks a significant breakthrough in our pursuit of innovative therapies for chronic diseases. By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension management where more compliant and safe treatment is needed to improve cardiovascular events and other comorbidities.”

Dr. Alex M. DePaoli, chief medical officer and executive vice president of translational medicine, added: “RN1871’s preclinical data showed potent AGT suppression which reduces blood pressure significantly with a favourable safety profile. We plan to advance RN1871 into Phase I trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in humans. This progress reflects our team’s expertise in translating scientific insights into clinical solutions.”

Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!